Literature DB >> 18187873

Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas.

Ryo Morimoto1, Fumitoshi Satoh, Osamu Murakami, Takashi Suzuki, Takaaki Abe, Masayuki Tanemoto, Michiaki Abe, Akira Uruno, Shigeto Ishidoya, Yoichi Arai, Kazuhiro Takahashi, Hironobu Sasano, Sadayoshi Ito.   

Abstract

Adrenocortical carcinoma (ACC) is a rare, highly malignant tumor. The aim of the present study is to evaluate the prognostic relevance of a proliferation marker Ki67/MIB1 by immunohistochemistry in 17 cases who underwent resections of the primary tumors and diagnosed to have ACC at Tohoku University Hospital based on the criteria of Weiss during the period from 1976 to 2005. The follow-up periods ranged from 221 days to 10659 days (about 29 years) with the median of 1895 days. The median age at diagnosis was 46 years old, and the mean size of the primary tumors was 7.1 cm with the minimal of 3.5 cm. Ki67/MIB1 labeling index (Ki67/MIB1LI) ranged from 1% to 26%. Kaplan-Meier analysis revealed that patients with Ki67/MIB1LI of 7% or more were associated with significantly shortened disease-free survival (P = 0.0037). The evaluation with Weiss criteria revealed that the median score of Weiss criteria was five, and 13 patients (76.5%) presented positive findings in the criteria of mitotic rate. The survival analysis with Weiss score showed that patients with the scores of 6 or more had both significantly shortened disease-free survival (P = 0.0001) and overall survival (P = 0.0063). The present study has suggested that Ki67/MIB1LI, as well as Weiss score, is a useful predictor for tumor recurrence after resection of the primary tumors in patients with ACC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18187873     DOI: 10.1507/endocrj.k07-079

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  37 in total

1.  Presence of kisspeptin-like immunoreactivity in human adrenal glands and adrenal tumors.

Authors:  Kazuhiro Takahashi; Itaru Shoji; Akiko Shibasaki; Ichiro Kato; Keisuke Hiraishi; Hajime Yamamoto; Kiriko Kaneko; Osamu Murakami; Ryo Morimoto; Fumitoshi Satoh; Sadayoshi Ito; Kazuhito Totsune
Journal:  J Mol Neurosci       Date:  2009-11-07       Impact factor: 3.444

2.  Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).

Authors:  A Stigliano; I Chiodini; R Giordano; A Faggiano; L Canu; S Della Casa; P Loli; M Luconi; F Mantero; M Terzolo
Journal:  J Endocrinol Invest       Date:  2015-07-14       Impact factor: 4.256

3.  Operative Management of Recurrent and Metastatic Adrenocortical Carcinoma: A Systematic Review.

Authors:  Winifred M Lo; Christine M Kariya; Jonathan M Hernandez
Journal:  Am Surg       Date:  2019-01-01       Impact factor: 0.688

Review 4.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

5.  PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma.

Authors:  Emilien Billon; Pascal Finetti; Alexandre Bertucci; Patricia Niccoli; Daniel Birnbaum; Emilie Mamessier; François Bertucci
Journal:  Oncoimmunology       Date:  2019-08-28       Impact factor: 8.110

6.  Pathology of the adrenal cortex: a reappraisal of the past 25 years focusing on adrenal cortical tumors.

Authors:  Mauro Papotti; Eleonora Duregon; Marco Volante; Anne Marie McNicol
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

Review 7.  Immunohistochemical Biomarkers of Adrenal Cortical Neoplasms.

Authors:  Ozgur Mete; Sylvia L Asa; Thomas J Giordano; Mauro Papotti; Hironobu Sasano; Marco Volante
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

8.  [Diagnostic pitfalls with Cushing's syndrome].

Authors:  W Hunger-Battefeld; M Gajda; A Hansch; A Mandecka; U A Müller; G Wolf
Journal:  Internist (Berl)       Date:  2010-03       Impact factor: 0.743

9.  Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling.

Authors:  Thomas J Giordano; Rork Kuick; Tobias Else; Paul G Gauger; Michelle Vinco; Juliane Bauersfeld; Donita Sanders; Dafydd G Thomas; Gerard Doherty; Gary Hammer
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

10.  A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma.

Authors:  Mouhammed Amir Habra; Shamim Ejaz; Lei Feng; Prajnan Das; Ferhat Deniz; Elizabeth G Grubbs; Alexandria Phan; Steven G Waguespack; Montserrat Ayala-Ramirez; Camilo Jimenez; Nancy D Perrier; Jeffrey E Lee; Rena Vassilopoulou-Sellin
Journal:  J Clin Endocrinol Metab       Date:  2012-11-12       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.